Shipping update: orders placed before Friday, Aug 7, 10:00 AM (Bangkok time) are dispatched the same day. Orders placed after that are dispatched on Tuesday, Aug 11.
AOD-9604 research peptide – AOD9604 (Anti-Obesity Drug 9604) is a synthetic fragment of

AOD-9604

AOD9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone (HGH) that targets fat metabolism without raising IGF-1.

Fat Loss
In Stock

Total Price

฿1300

CardCrypto−5%Revolut · Wise · PayPalEncrypted checkout

Prefer Revolut, Wise or PayPal?

For research & laboratory use only. Not for human consumption.

Half-Life

30-60 minutes

Administration Route

Subcutaneous injection

Targeted Fat Breakdown

Activates lipolysis without stimulating IGF-1 or growth

No Glucose Impact

Does not affect blood sugar or insulin sensitivity

Growth Factor Activity

Retains bone-protective effects of HGH C-terminal fragment

Effect Timeline

Start — Week 2

Lipolytic signalling active; fat cell metabolism increases

Week 4

Stubborn fat deposits begin mobilising

Week 8

Visible reduction in body fat %, especially peripherally

Week 12

Sustained fat loss without lean mass loss confirmed

Mechanism of Action

AOD9604 is a modified peptide built from the final amino acids (177-191) of human growth hormone, with a tyrosine added at position 177 for stability. This C-terminal fragment keeps the fat-mobilising (lipolytic) and fat-storage-blocking (anti-lipogenic) actions of intact HGH, yet omits the N-terminal region that triggers IGF-1 release. Because IGF-1 is not stimulated, AOD9604 avoids the anabolic and blood-sugar-raising (diabetogenic) effects of full growth hormone. Research indicates it acts on beta-3 adrenergic receptors in adipocytes, switching on lipolysis and suppressing lipogenesis through a pathway that is independent of the growth-promoting HGH signal.

Scientific Research

1
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone

Horm Res (2000)

2
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

Int J Obes Relat Metab Disord (2001)

3
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

Endocrinology (2001)

Why Researchers Choose AOD9604

AOD9604 is studied wherever the goal is to isolate the fat-metabolising action of human growth hormone from its growth-promoting effects. Because the HGH fragment drives lipolysis without raising IGF-1, insulin or glucose, it is a clean tool for fat-metabolism research:

  • Selective adipose-tissue lipolysis without IGF-1 or anabolic confounders
  • Comparative lipolysis pharmacology against intact HGH and the related fragment 176-191
  • Beta-3 adrenergic receptor activity studies in adipocytes
  • Lipogenesis inhibition and fat-cell differentiation research
  • Metabolic syndrome and abdominal-adiposity investigations
  • Long-term safety profiling of lipolytic peptide fragments

Reconstitution and Storage

Reconstitution: use bacteriostatic water (1 to 2ml); swirl gently until the powder fully dissolves, do not shake. After reconstitution: keep refrigerated (2-8°C), use within 28 days, do not freeze, and protect from direct light.

Dosing at a Glance

Route

Subcutaneous injection

Frequency

Once daily

Typical research dose

250–500 mcg

Calculate dosage

Opens the calculator with this peptide preselected. Research reference only.

Product FAQs

Research Tools

Dosing Calculator

Concentration & syringe units

Injection Guide

8-step visual protocol

Peptide Finder

Find the right peptide

Cart

Your cart is empty